The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Gemcitabine (G) and nab-paclitaxel (nab-P) in patients with refractory advanced pancreatic cancer (PC).
Vinicius Ernani
No relevant relationships to disclose
Ikechukwu Immanuel Akunyili
No relevant relationships to disclose
Peter Joel Hosein
No relevant relationships to disclose
Jessica Macintyre
No relevant relationships to disclose
Caio Max S. Rocha Lima
No relevant relationships to disclose